BIOTECanada

BIONATION 2024 Recap: Showcasing Canada’s Biotech Ecosystem 🌟   Canada’s biotech ecosystem gathered in Ottawa for BIONATION 2024 showcasing the sector's economic and social impact. Over the course of two days; BIONATION united leaders in science, innovation, and entrepreneurship with researchers, investors, policymakers, and the next generation of biotech professionals. The energy and enthusiasm across the ecosystem was undeniable, showcasing not just Canada’s potential, but its shared ambition to build world-class biotech companies on Canadian soil.   The event featured insightful panels on innovation, anchor companies, investment, and talent, along with fireside chats featuring BIOTECanada’s Andrew Casey with the Minister of Health, Hon. Mark Holland, PC, MP, a keynote from astronaut Chris Hadfield, and in a pivotal announcement exclusive to BIONATION 2024, Hon. François-Philippe Champagne, Minister of Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada, announced the creation of the Health Emergency Readiness Canada agency, a crucial step in bolstering the country's pandemic preparedness and enhancing collaboration between healthcare and innovation sectors. This announcement emphasized the need for health and economic policy to work together to fully leverage Canada’s advances in science and innovation.   The Takeaway: Canada has the tools, expertise, and drive to establish anchor companies and a collaborative, ambitious biotech future.   Thank You to our BIOTECanada Members, industry stakeholders, and especially the BIONATION Builders for making this event a success.   For a full recap of BIONATION 2024, and to view our photo gallery, visit: www.biotech.ca/BIONATION #BIONATION #BIONATION2024 #Canada #CdnPoli #innovation #biotech #biotechnology #events #health #lifesciences #investment #membership #ecosystem

Looking to expand your Ontario-based agri-food or agri-tech business? Bioenterprise Canada, with the support of Agriculture, Food and Agribusiness | Agriculture, Alimentation et Agroentreprise, invites Ontario organizations with agri-based products to lead Market Validation and Product Development Projects. Apply today for the opportunity to advance your research into the marketplace. Learn more and apply here: https://ow.ly/wj1850TPH4c #SustainableCdnAg #AgCanDurable

Pleased to have participated in the Canadian Association for Population Therapeutics (CAPT) conference, "Bridging the Gap to Access: Patient-Centered Care in Evolving Healthcare Systems." The event featured two highly productive days of discussions on pressing health system issues, including: ✔️ Access to drugs for rare diseases ✔️ The critical role of data in determining value, including for Outcomes- Based Agreements, and ✔️ The need to assess and enhance health system readiness for new and advanced therapies During the conference, BIOTECanada, represented by Isra Wani, and Canada's Drug Agency (CDA-AMC) presented a poster on our recent collaborative project. Together, BIOTECanada and CDA-AMC developed and tested a strategic foresight framework, offering key recommendations to guide the health system as it navigates the introduction of Advanced Therapeutic Products (ATPs). BIOTECanada members valued the opportunity to work with CDA-AMC to support system readiness for ATPs in Canada; this project represents a significant milestone in the collaboration between CDA-AMC and industry. View the scientific poster here: https://lnkd.in/eQ8dg95T  

Congratulations to BIOTECanada member Alpha-9 Oncology team on their impressive $175 million Series C financing. This milestone highlights the importance of continued investment in the biotech sector, fueling the development of cutting-edge therapies and strengthening the broader ecosystem. #Biotech #Investment #Radiopharmaceuticals #Ecosystem #Innovation

Congratulations to BIOTECanada member Epitopea on the successful closing of its $31 million pre-Series A financing. This significant investment highlights the importance of capital in advancing the strategic development of innovative therapies while supporting the continued growth of Canada’s biotech ecosystem. #Investment #Biotech #Innovation #Canada

Congratulations to BIOTECanada member Find Therapeutics on achieving a major milestone with the first dose administration of FTX-101, a First-in-Class remyelinating agent for chronic optic neuropathy, in Phase 1 clinical trials. After an impactful presentation at the BIOTECanada Investment Summit this past March and securing CAD 11 million in convertible debenture financing, this milestone highlights their dedication to advancing innovative therapies. It also showcases the strength of Canada’s biotech ecosystem, where strategic investments drive cutting-edge developments, boost economic growth, and reinforce Canada's position as a global leader in life sciences.

Congratulations to BIOTECanada member Zymeworks Inc. on dosing the first patient in their Phase 1 clinical trial of ZW171, a promising therapy for mesothelin-expressing cancers including ovarian cancer and NSCLC. This milestone underscores Zymeworks’ commitment to advancing innovative cancer treatments and highlights the critical role of Canadian biotech companies in driving global progress in life sciences. Kudos to the entire team!

A unique opportunity to pitch your company to global investors, venture capitalists, and strategic partners. This Summit by our partners at OBIO is a great platform for early-stage and venture-backed companies looking to scale and grow within Canada's biotech ecosystem. Apply now and take advantage of this opportunity to drive your company's growth and contribute to the expansion of Canada's biotechnology sector.

Pleased to showcase the work of our 2024 BIONATION Builders. The final organization we're featuring is the CASTL - Canadian Alliance for Skills and Training in Life Sciences CASTL is dedicated to developing highly qualified personnel for Canada’s expanding biomanufacturing sector. Their mission is to equip individuals and teams with technical skills through world-class training programs tailored to meet industry needs. They offer flexible training options, including onsite, online, and on-demand modules, ensuring accessibility for all employees—from entry-level to senior management. Their state-of-the-art facilities in Montreal, Charlottetown, and Vancouver simulate real-world GMP environments, enhancing the learning experience. As the exclusive provider of NIBRT’s internationally recognized curriculum, CASTL delivers the gold standard in biomanufacturing training. By partnering with CASTL, you not only nurture your workforce but also enhance job satisfaction and retention. Their commitment to quality and customized training solutions empowers your organization to meet the challenges of tomorrow’s biomanufacturing industry, all while fostering a culture of continuous improvement and operational excellence. Read more about CASTL here: https://lnkd.in/ejVs8qMc Read more about BIONATION, here: https://lnkd.in/dUeJCWJC #biotechnology #ecosystem #biotech #canada #innovation #publicpolicy #cdnpoli #bionation2024 #BIONATIONBuilder #BIONATION #BIONATION2024

BIOTECanada is pleased to announce three new members joining the Board of Directors: Anne Woods, MA, CFA, (Managing Director, Life Sciences, Banking at RBCx); Tamer Mohamed, (Founder & CEO at Aspect Biosystems); and Karen Heim, (Vice President and General Manager, Canada at Alexion Pharmaceuticals, Inc.). “We are delighted to welcome Anne, Tamer, and Karen to BIOTECanada’s Board of Directors. Their combined expertise will enhance our efforts to attract investment, establish Canada as a regulatory leader, and scale up biotech companies,” said Andrew Casey, President & CEO, BIOTECanada. “Their backgrounds in finance, innovation, healthcare, and commercialization will be vital as we continue to advocate for Canada’s thriving biotech sector.” Read the full press release here: https://lnkd.in/eyjFNJPn